Neuromodulation for Functional Recovery After Stroke (VNS-EARLY)
This study used a multicenter, double-blind, randomized controlled design. The trial protocol was jointly designed by the principal investigator and an executive committee composed of experts in functional neurosurgery, cerebrovascular disease, and rehabilitation medicine. The study enrolled patients in the subacute phase (3-6 months) after ischemic stroke with upper limb motor impairment. All patients were implanted with a vagus nerve stimulation (VNS) device and randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group.
This study used the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity. The primary endpoint was the difference in FMA-UE score between the active VNS group and the control group at the end of 6 weeks of hospital treatment. Secondary endpoints included changes from baseline in FMA-UE score and WMFT score at 90 days, among others. This study evaluates the safety and efficacy of vagus nerve stimulation for improving upper limb motor function in patients in the subacute phase after stroke, ultimately providing clinical evidence for the diagnosis and treatment of this patient population.
調査の概要
詳細な説明
This study uses a multicenter, double-blind, randomized controlled design. Eligible participants all undergo implantation of a VNS device and are randomly assigned to an active VNS (0.8 mA) group combined with upper limb rehabilitation or a control VNS (0.0 mA) group. The study hypothesizes that vagus nerve stimulation is effective in improving upper limb motor function in patients in the subacute phase after stroke; that is, a meaningful difference in FMA-UE scores exists between the active VNS group and the control group at the end of 6 weeks of hospital treatment. All enrolled participants undergo implantation of a vagus nerve stimulation device. After preoperative assessment, patients undergo implantation of the vagus nerve stimulation device under general anesthesia. After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). This trial uses the FMA-UE score, WMFT score, and other measures to assess changes in impairment severity, with a pretreatment baseline assessment performed 1 week after implantation. Stimulation testing is performed in 0.1 mA increments in both groups to assess the level at which participants can perceive and tolerate stimulation. Hospital treatment begins on the day after baseline assessment.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Xuesong Bai, Dr.
- 電話番号:86 18810032664
- メール:bxsben@163.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- History of unilateral supratentorial ischemic stroke and in the subacute phase (3-6 months);
- Age between 18-80 years, both male and female;
- FMA-UE score of 20-50 (inclusive);
- Ability to communicate, understand, and provide appropriate consent; participant can follow two-step commands;
- Right or left upper limb weakness;
- Active flexion/extension of the wrist or fingers;
- Informed consent signed by the patient or a family member.
Exclusion Criteria:
- History of hemorrhagic stroke;
- Persistent dysphagia or choking/coughing while eating or drinking;
- Medications that, at study initiation, may significantly interfere with the effects of VNS on neurotransmitter systems;
- Prior vagus nerve injury, bilateral or unilateral (e.g., injury during carotid endarterectomy);
- Severe or more severe depression (Beck Depression Inventory >29);
- Candidates unsuitable for device implantation surgery (e.g., history of adverse reaction to anesthesia, deemed unsuitable as a surgical candidate by the surgeon, etc.);
- Current use of any other stimulation device, such as a pacemaker or other neurostimulator; current use of any other investigational device or drug;
- Preexisting neurological or psychiatric disorders before stroke onset that affect assessment of the condition;
- Pregnancy, planned pregnancy, or breastfeeding during the study period;
- Severe upper limb spasticity (modified Ashworth ≥3);
- Severe sensory loss. Sensory loss will be measured using the upper extremity sensory portion of the Fugl-Meyer Assessment. The assessment involves light touch (two items) and proprioception (four items). The maximum score is 12; subjects with a score below 6 will be excluded from the study;
- Other conditions that the investigator considers unsuitable for participation or that may pose a significant risk to the patient.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Active VNS group
After implantation, participants randomized to active VNS (0.8 mA) combined with upper limb rehabilitation. |
After implantation, participants are randomized 1:1 to active VNS (0.8 mA) combined with upper limb rehabilitation or control VNS (0.0 mA). To reduce the risk of participants inferring treatment assignment, participants in both treatment groups receive five stimuli of decreasing intensity at the beginning of each treatment session (starting at 0.8 mA and then decreasing by 0.1 mA at each step), after which treatment is administered according to randomization. |
|
偽コンパレータ:Control VNS group
After implantation, participants randomized to control VNS (0 mA) combined with upper limb rehabilitation. |
After implantation, participants randomized to Control VNS (0.8 mA) combined with upper limb rehabilitation. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
The difference in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) scores between the active VNS group and the control group at the end of 6 weeks of hospital treatment.
時間枠:At the end of 6 weeks of hospital treatment.
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
At the end of 6 weeks of hospital treatment.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Clinically meaningful improvement in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days (≥6-point improvement in FMA-UE score);
時間枠:90 days
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
90 days
|
|
Change from baseline in Wolf Motor Function Test (WMFT) score at 90 days
時間枠:90 days
|
The WMFT Functional Ability Scale ranges from 0 to 75, with higher scores indicating better upper-extremity function. |
90 days
|
|
Change from baseline in Fugl-Meyer Assessment-Upper Extremity (FMA-UE) at 90 days
時間枠:90 days
|
The FMA-UE total score ranges from 0 to 66, with higher scores indicating better upper-extremity motor function. |
90 days
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change from baseline in Stroke Impact Scale (SIS) score at 90 days
時間枠:90 days
|
The SIS score ranges from 0 to 100, with higher scores indicating better health status and functioning. |
90 days
|
|
Change from baseline in Stroke-Specific Quality of Life (SS-QOL) score at 90 days
時間枠:90 days
|
The SS-QOL total score ranges from 49 to 245, with higher scores indicating better quality of life. |
90 days
|
|
Change from baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) utility index score at 90 days
時間枠:90 days
|
The EuroQol 5-Dimension 5-Level utility index ranges from -0.391 to 1.000, with higher scores indicating better health-related quality of life. |
90 days
|
|
Change from baseline in Motor Activity Log (MAL) score at 90 days
時間枠:90 days
|
Each MAL subscale ranges from 0 to 5, with higher scores indicating better real-world use and movement quality of the affected upper extremity. |
90 days
|
|
Change from baseline in Beck Depression Inventory (BDI) total score at 90 days
時間枠:90 days
|
The BDI total score ranges from 0 to 63, with higher scores indicating more severe depressive symptoms and therefore a worse outcome. |
90 days
|
|
Adverse events: adverse events occurring during the study period (including the surgical procedure);
時間枠:From study enrollment through the Day 90 follow-up visit, including the perioperative period.
|
From study enrollment through the Day 90 follow-up visit, including the perioperative period.
|
|
|
Device complications: any unexpected adverse reactions of the device
時間枠:From device implantation through the Day 90 follow-up visit.
|
From device implantation through the Day 90 follow-up visit.
|
協力者と研究者
スポンサー
出版物と役立つリンク
一般刊行物
- 1. 王拥军, et al., 中国卒中报告2019(中文版)(1). 中国卒中杂志, 2020. 15(10): p. 1037-1043. 2. Nakayama, H., et al., Recovery of upper extremity function in stroke patients: The Copenhage n stroke study. Archives of Physical Medicine and Rehabilitation. 75(4): p. 394-398. 3. Opara, J.A. and K. Jaracz, Quality of life of post-stroke patients and their caregivers. J Med Life, 2010. 3(3): p. 216-20. 4. Butt, M.F., et al., The anatomical basis for transcutaneous auricular vagus nerve stimulation. J Anat, 2020. 236(4): p. 588-611. 5. van der Meij, A. and M.J.H. Wermer, Vagus nerve stimulation: a potential new treatment for ischaemic strok e. Lancet (London, England). 397(10284): p. 1520-1521. 6. Ay, I., et al., Transcutaneous Cervical Vagus Nerve Stimulation Ameliorates Acute Isch emic Injury in Rats. Brain stimulation. 9(2): p. 166-73. 7. Kimberley, T.J., et al., Vagus Nerve Stimulation Paired With Upper Limb Rehabilitation After Ch ronic Stroke. Stroke. 49(11): p. 2789-2792. 8. Dawson, J., et al., Safety, Feasibility, and Efficacy of Vagus Nerve Stimulation Paired With Upper-Limb Rehabilitation After Ischemic Stroke. Stroke, 2016. 47(1): p. 143-50. 9. Dawson, J., et al., Vagus nerve stimulation paired with rehabilitation for upper limb motor function after ischaemic stroke (VNS-REHAB): a randomised, blinded, pivotal, device trial. Lancet, 2021. 397(10284): p. 1545-1553. 10. Grefkes, C. and G.R. Fink, Recovery from stroke: current concepts and future perspectives. Neurological Research and Practice, 2020. 2(1): p. 17.
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- VNS-EARLY
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The VNS-EARLY Steering Committee will consider on a case-by-case basis requests for data sharing.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。